Vical Incorporated (NASDAQ:VICL) received a $9.00 target price from research analysts at HC Wainwright in a research report issued to clients and investors on Monday. The brokerage currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price objective would indicate a potential upside of 273.44% from the stock’s current price.

Separately, Rodman & Renshaw restated a “buy” rating and set a $9.00 price objective on shares of Vical in a report on Monday.

Vical (VICL) traded down 1.5726% during trading on Monday, reaching $2.3721. The company had a trading volume of 66,228 shares. The stock’s market cap is $26.32 million. Vical has a 12-month low of $2.05 and a 12-month high of $4.80. The firm has a 50-day moving average price of $2.31 and a 200 day moving average price of $2.27.

Vical (NASDAQ:VICL) last posted its quarterly earnings data on Monday, May 15th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by $0.07. Vical had a negative return on equity of 21.06% and a negative net margin of 71.38%. The company had revenue of $3.21 million for the quarter. Equities research analysts predict that Vical will post ($1.03) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was first reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/06/13/vical-incorporated-vicl-pt-set-at-9-00-by-hc-wainwright.html.

Several hedge funds and other institutional investors have recently bought and sold shares of VICL. Renaissance Technologies LLC increased its position in Vical by 29.8% in the first quarter. Renaissance Technologies LLC now owns 2,073,599 shares of the biotechnology company’s stock valued at $811,000 after buying an additional 476,499 shares during the last quarter. ClariVest Asset Management LLC acquired a new stake in Vical during the second quarter worth $208,000. FMR LLC boosted its stake in Vical by 1.8% in the fourth quarter. FMR LLC now owns 1,006,875 shares of the biotechnology company’s stock worth $2,316,000 after buying an additional 17,967 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in Vical by 7.2% in the first quarter. Vanguard Group Inc. now owns 219,811 shares of the biotechnology company’s stock worth $490,000 after buying an additional 14,818 shares during the last quarter. Institutional investors own 23.65% of the company’s stock.

Vical Company Profile

Receive News & Ratings for Vical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.